Clinical research trials and the treatment of hypoactive sexual desire disorder
Although the concept of a female sexual dysfunction market has been a popular area of research for the last decade, there is only one drug approved by FDA for the treatment of low desire among women in the United States. Despite advancements in the understanding of psychopharmacology and pathways involved in women's sexual response, pharmaceutical companies continue to face unique challenges when investigating treatments for low desire. The current framework used to define and measure low desire is still under debate and thus makes it challenging to properly measure the efficacy of a proposed drug treatment. This review, along with an analysis of the clinical outcomes of previous drug trials not approved by FDA for the treatment of HSDD, aims to provide comprehensive recommendations for the research and treatment of low desire that could improve future drug trial designs, develop necessary data to support approval of effective treatments and ultimately help the millions of women seeking treatment.